Response markers and the molecular mechanisms of action of Gleevec in gastrointestinal stromal tumors.
暂无分享,去创建一个
Andrew K Godwin | Jonathan Fletcher | J. Fletcher | A. Godwin | B. Eisenberg | J. Arnoletti | M. von Mehren | M. Ochs | Z. Pan | A. Frolov | O. Favorova | Margaret von Mehren | Juan Pablo Arnoletti | Andrey Frolov | Burton Eisenberg | Michael Ochs | Santiago Chahwan | Zhong-Zong Pan | Olga Favorova | S. Chahwan | J. P. Arnoletti
[1] Pierre R. Bushel,et al. STATISTICAL ANALYSIS OF A GENE EXPRESSION MICROARRAY EXPERIMENT WITH REPLICATION , 2002 .
[2] F. Ruddle,et al. Primary structure of c‐kit: relationship with the CSF‐1/PDGF receptor kinase family–oncogenic activation of v‐kit involves deletion of extracellular domain and C terminus. , 1988, The EMBO journal.
[3] R. DeMatteo,et al. Two hundred gastrointestinal stromal tumors: recurrence patterns and prognostic factors for survival. , 2000, Annals of surgery.
[4] K Y Hui,et al. A specific inhibitor of phosphatidylinositol 3-kinase, 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one (LY294002). , 1994, The Journal of biological chemistry.
[5] L. Ashman,et al. KIT gene mutations in gastrointestinal stromal tumors: more complex than previously recognized? , 2002, The American journal of pathology.
[6] J. Fletcher,et al. KIT extracellular and kinase domain mutations in gastrointestinal stromal tumors. , 2000, The American journal of pathology.
[7] A. D. Van den Abbeele,et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. , 2002, The New England journal of medicine.
[8] J. Pei,et al. The role of phosphodiesterase in mediating the effect of protein kinase C on cyclic AMP accumulation upon kappa-opioid receptor stimulation in the rat heart. , 2000, The Journal of pharmacology and experimental therapeutics.
[9] D. Botstein,et al. Cluster analysis and display of genome-wide expression patterns. , 1998, Proceedings of the National Academy of Sciences of the United States of America.
[10] J. Lasota,et al. Gastrointestinal stromal tumors: recent advances in understanding of their biology. , 1999, Human pathology.
[11] J. Rumessen,et al. Light- and electron microscopical studies of interstitial cells of Cajal and muscle cells at the submucosal border of human colon. , 1993, Laboratory investigation; a journal of technical methods and pathology.
[12] B. Druker,et al. Inhibition of c-kit receptor tyrosine kinase activity by STI 571, a selective tyrosine kinase inhibitor. , 2000, Blood.
[13] B. Furman,et al. The role of the cyclic GMP-inhibited cyclic AMP-specific phosphodiesterase (PDE3) in regulating clonal BRIN-BD11 insulin secreting cell survival. , 2000, Cellular signalling.
[14] D. Botstein,et al. For Personal Use. Only Reproduce with Permission from the Lancet Publishing Group , 2022 .
[15] P S Meltzer,et al. Gastrointestinal stromal tumors with KIT mutations exhibit a remarkably homogeneous gene expression profile. , 2001, Cancer research.
[16] B. Druker,et al. STI571 (Gleevec) as a paradigm for cancer therapy. , 2002, Trends in molecular medicine.
[17] E. Degerman,et al. Important Role of Phosphodiesterase 3B for the Stimulatory Action of cAMP on Pancreatic β-Cell Exocytosis and Release of Insulin* , 2002, The Journal of Biological Chemistry.
[18] D. Fabbro,et al. Imatinib: a selective tyrosine kinase inhibitor. , 2002, European journal of cancer.
[19] M. Baccarani,et al. Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. , 2002, The New England journal of medicine.
[20] D J Glass,et al. Identification of Ubiquitin Ligases Required for Skeletal Muscle Atrophy , 2001, Science.
[21] A. Godwin,et al. Identification of two candidate tumor suppressor genes on chromosome 17p13.3. , 1996, Cancer Research.
[22] M. Baccarani,et al. Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study. , 2002, Blood.
[23] B. Druker,et al. Abl protein-tyrosine kinase inhibitor STI571 inhibits in vitro signal transduction mediated by c-kit and platelet-derived growth factor receptors. , 2000, The Journal of pharmacology and experimental therapeutics.
[24] A. Goldberg,et al. Atrogin-1, a muscle-specific F-box protein highly expressed during muscle atrophy , 2001, Proceedings of the National Academy of Sciences of the United States of America.
[25] M. Kohno,et al. ERK pathway positively regulates the expression of Sprouty genes. , 2001, Biochemical and biophysical research communications.
[26] Sigrid Stroobants,et al. Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumours: a phase I study , 2001, The Lancet.
[27] R. Larson,et al. Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study. , 2002, Blood.
[28] A. Godwin,et al. γ-Synuclein Promotes Cancer Cell Survival and Inhibits Stress- and Chemotherapy Drug-induced Apoptosis by Modulating MAPK Pathways* , 2002, The Journal of Biological Chemistry.
[29] T. Jacks,et al. STI571 inactivation of the gastrointestinal stromal tumor c-KIT oncoprotein: biological and clinical implications , 2001, Oncogene.
[30] Samuel Singer,et al. PDGFRA Activating Mutations in Gastrointestinal Stromal Tumors , 2003, Science.
[31] Trey Ideker,et al. Testing for Differentially-Expressed Genes by Maximum-Likelihood Analysis of Microarray Data , 2000, J. Comput. Biol..
[32] M. V. van Velthuysen,et al. The histopathological differential diagnosis of gastrointestinal stromal tumours , 2001, Journal of clinical pathology.
[33] J. Lasota,et al. Mutations in exon 11 of c-Kit occur preferentially in malignant versus benign gastrointestinal stromal tumors and do not occur in leiomyomas or leiomyosarcomas. , 1999, The American journal of pathology.
[34] C. J. Chen,et al. KIT activation is a ubiquitous feature of gastrointestinal stromal tumors. , 2001, Cancer research.
[35] D. Glass. Signalling pathways that mediate skeletal muscle hypertrophy and atrophy , 2003, Nature Cell Biology.
[36] Jürg Zimmermann,et al. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr–Abl positive cells , 1996, Nature Medicine.
[37] A. Godwin,et al. DNA array‐based method for detection of large rearrangements in the BRCA1 gene , 2002, Genes, chromosomes & cancer.
[38] G. Piazza,et al. Exisulind induction of apoptosis involves guanosine 3',5'-cyclic monophosphate phosphodiesterase inhibition, protein kinase G activation, and attenuated beta-catenin. , 2000, Cancer research.